Effect of selective estrogen receptor modulators on estrogen-sensitive tissues;Wirkung von selektiven ostrogen-rezeptor-modulatoren auf ostrogensensitive gewebe

Gynakologisch-geburtshilfliche Rundschau

Volumn 39, Issue 4, 1999, Pages 184-190

  Jirecek, Stefan ^a   Pavo, Imre ^b   Huber, Johannes C ^a  

^a UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

^b UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Breast cancer; Droloxifene; Endometrium; Estrogen receptor; Idoxifene; Raloxifene; Selective estrogen receptor modulators; Tamoxifen; Toremifene

Indexed keywords

DROLOXIFENE; IDOXIFENE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE;

BREAST CANCER; CANCER RISK; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG STRUCTURE; ENDOMETRIUM CANCER; HUMAN; HYPERTROPHY; REVIEW;

EID: 0033401268     PISSN: 10188843     EISSN: None     Source Type: Journal    
DOI: 10.1159/000022308     Document Type: Review

References (41)

1. Berry M, Metzger D, Chambon P: Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J 1990;9:2811-2818.
2. Katzenellenbogen BS, Montano MM, Le Goff P, Schodin DJ, Kraus WL, Bhardwaj B, Fujimoto N: Antioestrogens: Mechanisms and actions in target cells. J Steroid Biochem Mol Biol 1995;53:387-393.
3. Kuiper G, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson J: Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996;93:5925-5930.
4. Mosselman S, Polman J, Dijkema R: ERβ identification and characterization of a novel human estrogen receptor. FEBS Lett 1996;392: 49-53.
5. Mitlak B, Cohen F: In search of optimal long-term female hormone replacement: The potential of selective estrogen receptor modulators. Horm Res 1997;48:155-163.
6. Gustafsson J: Therapeutic potential of selective estrogen receptor modulators. Curr Opin Chem Biol 1998;2:508-511.
7. Korach K, Couse J, Curtis S, Washburn T, Lindzey J, Kimbro K, Eddy E, Migliaccio S, Sncdeker S, Lubahn D: Estrogen receptor gene disruption: Molecular characterization and experimental and clinical phenotypes. Recent Prog Horm Res 1996;51:159-186.
8. Ogawa S, Lubahn D, Korach K, Pfaff D: Behavioral effects of estrogen receptor gene disruption in male mice. Proc Natl Acad Sci USA 1997;94:1476-1481.
9. Rissman E, Early A, Taylor J, Korach K, Lubahn D: Estrogen receptors are essential for female sexual receptivity. Endocrinology 1997; 138:507-510.
10. Iafrati M, Karas R, Aronovitz M, Kim S, Sullivan T, Lubahn D, O'Donnell T, Korach K, Mendelsohn M: Estrogen inhibits the vascular injury response in estrogen receptor alpha-deficient mice. Nat Med 1997;3:545-548.
11. Paech K, Webb P, Kuiper G, Nillson S, Gustafsson J, Kushner P, Scanlan T: Differential ligand activation of estrogen receptors ERα and ERβ at API sites. Science 1997;277:1508-1510.
12. Halachmi S, Marden E. Martin G, MacKay H, Abbondanza C, Brown M: Estrogen receptor associated proteins: Possible mediators of hormone-induced transcription. Science 1993; 264:1455-1458.
13. Brzozowski A, Ashley P, Dauter Z, Hubbard R, Bonn T, Engström O, Öhman L, Greene G, Gustafsson J, Carlquist M: Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997;389:753-758.
14. Katzenellenbogen J, O'Malley B, Katzenellenbogen B: Tripartite steroid hormone receptor pharmacology: Interaction with multiple effector sites as a basis for the cell-and promoter-specific action of these hormones. Mol Endocrinol 1996;10:119-131.
15. Yang N, Venugopalan M, Hardikar S, Glasebrook A: Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifene. Science 1996;273:1222-1225.
16. Powles T, Eeles R, Ashley S: Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998;352:98-101.
17. Sevelda P: Tamoxifen in the treatment of patients with breast cancer: Results of the latest meta-analysis of prospective randomized clinical trials. Gynäkol Geburtshilfliche Rundsch 1998;38:81-84.
18. Leeuwen F, Benraadt J: Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994;343:448-452.
19. McGonigle K, Shaw S, Vasilev S, Odom-Maryon T, Roy S, Simpson J: Abnormalities detected on transvaginal ultrasonography in tamoxifen-treated postmenopausal breast cancer patients may represent endometrial cystic atrophy. Am J Obstet Gynecol 1998;178:1145-1150.
20. Briley M, Lindsell D: The role of transvaginal ultrasound in the investigation of women with post-menopausal bleeding. Clin Radiol 1998; 53:502-505.
21. Berlière M, Charles A, Galant C, Donnez J: Uterine side effects of tamoxifen: A need for systematic pretreatment screening. Obstet Gynecol 1998;94:40-41.
22. Ke H, Chen K, Simmons H, Qi H, Crawford D: Comparative effects of droloxifene, tamoxifen and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model. Bone 1997;20:31-39.
23. Tonetti D, O'Regan R, Tanjore S, England G: Antiestrogen stimulated human endometrial cancer growth: Laboratory and clinical considerations. J Steroid Biochem Mol Biol 1998;65: 181-189.
24. Di Salle E, Zaccheo T, Ornati G: Antiestrogenic and antitumor properties of the new triphenylethylene derivative toremifen in the rat. J Chem Biochem 1990;36:203-206.
25. Changer S, McCague R, Lugmani Y: Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen: New analogues of the antioestrogen for the treatment of breast cancer. Cancer Res 191;51: 5851-5858.
26. Nuttall M, Bradbeer J, Stroup G, Nadeau D, Hoffman S, Zhao H, Rehm S, Gowen M: Idoxifene: A novel selective estrogen receptor modulator prevents bone loss and lowers cholesterol levels in ovariectomized rats and decreases uterine weight in intact rats. Endocrinology 1998;139:5224-5233.
27. Rippy M, Lee D, Pearson S, Bernai C: Identification of rhesus macaques with spontaneous endometriosis. J Med Primatol 1996;25:346-355.
28. Fanning P, Kuehl T, Lee R, Pearson S: Video mapping to assess efficacy of an antiestrogen (raloxifen) on spontaneous endometriosis in the rhesus monkey: Macaca mulatta; in Kuehl T (ed): Bunkley Day Proceedings. Temple, Texas A & M University Health Science Center, 1996, vol 6, pp 51-61.
29. Porter K, Tsibris J, Porter G: Raloxifen causes rapid regressions of abdominal wall leiomyomas in the estrogen induced pig model (abstract). J Soc Gynecol Invest 1996;3(suppl): 147.
30. Fuchs-Young R, Howe S: Inhibition of estrogen-stimulated growth of uterine leiomyomas by selective estrogen receptor modulators. Mol Carcinog 1996;17:151-159.
31. Giant M, Eisenhut C, Boss S, Draper M: A scale for assessing postmenopausal endometrial proliferation in response to potential or known selective estrogen receptor modulators. Am J Clin Pathol 1995;104:341-342.
32. Obermaier A, Jirecek S, Leodolter S: Epidemiologische Hinweise auf die Bedeutung von Hormonen in der Karzinogenese. Gynäkol Geburtshilfliche Rundsch 1998;38:73-79.
33. Jordan V: Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur J Cancer 1976;12: 419-425.
34. Cuzick J, Baum M: Tamoxifen and contralateral breast cancer. Lancet 1985;ii:282.
35. National Cancer Institute: Breast Cancer Prevention Trial Shows Major Benefit, Some Risk. http://cancertrials.nci.nih.gov.
36. Rausching W, Pritchard KI: Droloxifene, a new antiestrogen: Its role in metastatic breast cancer. Breast Cancer Res Treat 1994;31:83-94.
37. Styles G, Davis E, Lim C: Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P-450. Carcinogenesis 1994; 15:5-9.
38. Hayes DF, Van Zyl JA, Hacking A: Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol 1995;113:2556-2566.
39. Coombes RC, Haynes BP, Dowsett M: Idoxifene: Report of a phase I study in patients with metastatic breast cancer. Cancer Res 1995;55: 1070-1074.
40. Gradishar WJ, Glusman JE, Vogel CL, Mansi JL, Stuart NS, Carmichael J: Raloxifene HCl, an new endocrine agent, is active in estrogen receptor positive (ER+) metastatic breast cancer. Breast Cancer Res Treat 1997;46:53.
41. Early Breast Cancer Trial's Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 1998;351:1451-1467.